Thieme E-Books & E-Journals -
Diabetologie und Stoffwechsel, Table of Contents
Diabetologie und Stoffwechsel 2024; 19(S 01): S72-S73
DOI: 10.1055/s-0044-1785379
Abstracts | DDG 2024
Poster
Posterwalk 10 – GLP-1 Agonisten, Doppel- und Mehrfachagonisten bei Typ-2-Diabetes

Retatrutide, a triple GIP/GLP-1/glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes: a 36--week, phase 2 study

Authors

  • Tamer Coskun

    1   Eli Lilly and Company, Clinical Research – Incretins & Incretin Combinations, Indianapolis, IN, United States

  • Julio Rosenstock

    2   Velocity Clinical Research, Type 2 diabetes, Dallas, TX, United States

  • Juan Frias

    3   Velocity Clinical Research, Los Angeles, CA, Medical Director and Principal Investigator , Los Angeles, CA, United States

  • Ania M. Jastreboff

    4   Yale University, Diabetes and Endocrinology, New Haven, United States

  • Yu Du

    5   Eli Lilly and Company, Statistics – Diabetes, Indianapolis, IN, United States

  • Jitong Lou

    6   Eli Lilly and Company, Statistics, Indianapolis, IN, United States

  • Sirel Gurbuz

    7   Eli Lilly and Company, GPS UK Medical & Safety Science, Indianapolis, IN, United States

  • Mark L. Hartman

    8   Eli Lilly and Company, Clin Research-Diabetes & Complications, Indianapolis, IN, United States

  • Axel Haupt

    9   Eli Lilly and Company, Diabetes & Metabolic Research, Indianapolis, IN, United States

  • Zvonko Milicevic

    10   Eli Lilly and Company, Next Generation Incretins (NILEX), Indianapolis, IN, United States

  • Jochen Seufert

    11   Universitätsklinikum und Medizinische Fakultät, Department of Internal Medicine , Freiburg, Germany
eRefRecommend Article